Royal Bank of Canada
TCRX icon

Royal Bank of Canada’s TScan Therapeutics TCRX Stock Holding History

Royal Bank of Canada’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Sell
73
-301
-80% -$322 ﹤0.01% 7677
2025
Q4 		$0 Sell
374
-432
-54% -$625 ﹤0.01% 7630
2025
Q3 		$1K Buy
806
+737
+1,068% +$1.3K ﹤0.01% 7030
2025
Q2 		$0 Sell
69
-1,046
-94% -$1.51K ﹤0.01% 7340
2025
Q1 		$1K Sell
1,115
-1,110
-50% -$2.4K ﹤0.01% 6719
2024
Q4 		$7K Sell
2,225
-10,118
-82% -$45.9K ﹤0.01% 6460
2024
Q3 		$62K Buy
12,343
+8,732
+242% +$52.7K ﹤0.01% 5598
2024
Q2 		$21K Buy
+3,611
New +$28.4K ﹤0.01% 6065
2022
Q4 		– Sell
-184
Closed -$1K – 7707
2022
Q3 		$1K Buy
+184
New +$603 ﹤0.01% 7273
2022
Q2 		– Sell
-1,000
Closed -$3K – 7705
2022
Q1 		$3K Hold
1,000
– – ﹤0.01% 7404
2021
Q4 		$5K Hold
1,000
– – ﹤0.01% 7230
2021
Q3 		$8K Buy
+1,000
New +$9.27K ﹤0.01% 7036

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Royal Bank of Canada's TCRX Position: Q1 2026 in Review

Royal Bank of Canada reduced its TScan Therapeutics (TCRX) stake by 80% in Q1 2026, selling an estimated $322 and leaving 73 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7677.

Royal Bank of Canada first reported a position in TCRX in Q3 2021 and has held it in 12 quarters since. The position peaked at $62K in Q3 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Royal Bank of Canada held 73 shares of TScan Therapeutics worth $0 as of Q1 2026.
  • Royal Bank of Canada sold 301 TScan Therapeutics shares in Q1 2026, an estimated $322.
  • TScan Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7677 holding.
  • Royal Bank of Canada first reported a position in TScan Therapeutics in Q3 2021 and has held it in 12 quarters since.
  • Royal Bank of Canada's TScan Therapeutics position peaked at $62K in Q3 2024.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.